Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040729 | 0.92 | FDFT1 (0.53) | FDFT1TDP1NPY2RRAB9ANPC1 | |
| SCHEMBL17389542 | 0.86 | FDFT1 (0.58) | FDFT1TDP1CA12CA1CA2 | |
| SCHEMBL15952966 | 0.86 | CA12 (0.50) | FDFT1TDP1CA12CA1CA2 | |
| SCHEMBL248915 | 0.85 | RAB9A (0.50) | FDFT1TDP1RAB9ANPC1ALDH1A1 | |
| SCHEMBL4003420 | 0.85 | CA12 (0.59) | FDFT1TDP1CA12CA1CA2 | |
| SCHEMBL3154927 | 0.84 | NPY2R (0.48) | FDFT1NPY2RALDH1A1 | |
| SCHEMBL8040438 | 0.83 | NAMPT (0.54) | FDFT1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL17360240 | 0.83 | KMT2A (0.55) | TDP1RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28022173 | 0.82 | FDFT1 (0.53) | FDFT1TDP1CA12CA1CA2 | |
| SCHEMBL15231639 | 0.82 | FDFT1 (0.54) | FDFT1TDP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | VALO HEALTH, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10730889-B2 | Amido spirocyclic amide and sulfonamide derivatives | FORMA TM, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20180339998-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | Valo Health, LLC | 2018-11-29 | — | — | US | disclosed |
| US-9822129-B2 | Amido spirocyclic amide and sulfonamide derivatives | GENENTECH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170216262-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | VALO EARLY DISCOVERY, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-2820008-B1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | GENENTECH INC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2401265-B1 | DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160002266-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002266-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | STS, AADAC, SULT2A1 | FDFT1 2123/4885TDP1 4383/4885CA12 945/4885 |
| US-20170216262-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | STS, AADAC, SULT2A1 | FDFT1 2123/4885TDP1 4383/4885CA12 945/4885 |
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | STS, AADAC, SULT2A1 | FDFT1 2123/4885TDP1 4383/4885CA12 945/4885 |
| US-20180339998-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | STS, AADAC, SULT2A1 | FDFT1 2123/4885TDP1 4383/4885CA12 945/4885 |
| US-10730889-B2 | Amido spirocyclic amide and sulfonamide derivatives | STS, AADAC, SULT2A1 | FDFT1 2123/4885TDP1 4383/4885CA12 945/4885 |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | FDFT1 525/4885TDP1 333/4885CA12 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.